| Code | CSB-MP008543HU1(M) |
| Abbreviation | Recombinant Human FCGR3A protein (F176V), partial (Active) |
| MSDS | |
| Size | $110 |
| Order now | |
| Image | |
| Have Questions? | Leave a Message or Start an on-line Chat |
CD16A mediates antibody-dependent cellular cytotoxicity and serves as a critical determinant of therapeutic antibody efficacy, with the F176V polymorphism conferring higher affinity for IgG1 and enhanced NK cell activation compared to the F176 variant. This recombinant protein, spanning the extracellular domain (aa 17–208) and produced in mammalian cells to preserve native glycosylation patterns, demonstrates a binding affinity of 12 nM to an anti-CD16A antibody in biolayer interferometry assays, confirming proper conformational integrity of the ligand-binding interface. The validated interaction kinetics support its use in therapeutic antibody epitope mapping, competitive inhibition screening to identify blocking candidates, and affinity characterization by SPR or BLI for antibody-receptor interaction studies. With purity exceeding 95% by SDS-PAGE and endotoxin levels below 1.0 EU/μg, this protein meets the quality thresholds commonly required for quantitative binding assays and serves as a positive control in ADCC-related functional studies.
There are currently no reviews for this product.